Literature DB >> 10807669

Modulation of (3)H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and beta-adrenoceptors in mouse tissues.

A U Trendelenburg1, S L Cox, V Schelb, W Klebroff, L Khairallah, K Starke.   

Abstract

Release-modulating opioid and cannabinoid (CB) receptors, beta-adrenoceptors and bradykinin receptors at noradrenergic axons were studied in mouse tissues (occipito-parietal cortex, heart atria, vas deferens and spleen) preincubated with (3)H-noradrenaline. Experiments using the OP(1) receptor-selective agonists DPDPE and DSLET, the OP(2)-selective agonists U50488H and U69593, the OP(3)-selective agonist DAMGO, the ORL(1) receptor-selective agonist nociceptin, and a number of selective antagonists showed that the noradrenergic axons innervating the occipito-parietal cortex possess release-inhibiting OP(3) and ORL(1) receptors, those innervating atria OP(1), ORL(1) and possibly OP(3) receptors, and those innervating the vas deferens all four opioid receptor types. Experiments using the non-selective CB agonists WIN 55,212-2 and CP 55,940 and the CB(1)-selective antagonist SR 141716A indicated that the noradrenergic axons of the vas deferens possess release-inhibiting CB(1) receptors. Presynaptic CB receptors were not found in the occipito-parietal cortex, in atria or in the spleen. Experiments using the non-selective beta-adrenoceptor agonist isoprenaline and the beta(2)-selective agonist salbutamol, as well as subtype-selective antagonists, demonstrated the occurrence of release-enhancing beta(2)-adrenoceptors at the sympathetic axons of atria and the spleen, but demonstrated their absence in the occipito-parietal cortex and the vas deferens. Experiments with bradykinin and the B(2)-selective antagonist Hoe 140 showed the operation of release-enhancing B(2) receptors at the sympathetic axons of atria, the vas deferens and the spleen, but showed their absence in the occipito-parietal cortex. The experiments document a number of new presynaptic receptor locations. They confirm and extend the existence of marked tissue and species differences in presynaptic receptors at noradrenergic neurons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807669      PMCID: PMC1572066          DOI: 10.1038/sj.bjp.0703305

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

Review 1.  Regulation of noradrenaline release by presynaptic receptor systems.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1977       Impact factor: 5.545

2.  Bradykinin and postganglionic sympathetic transmission.

Authors:  K Starke; B A Peskar; K A Schumacher; H D Taube
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-08       Impact factor: 3.000

3.  Determination of activity for nociceptin in the mouse vas deferens.

Authors:  I P Berzetei-Gurske; R W Schwartz; L Toll
Journal:  Eur J Pharmacol       Date:  1996-04-29       Impact factor: 4.432

4.  A new example of a morphine-sensitive neuro-effector junction: adrenergic transmission in the mouse vas deferens.

Authors:  G Henderson; J Hughes; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1972-12       Impact factor: 8.739

5.  The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551).

Authors:  A J Bilski; S E Halliday; J D Fitzgerald; J L Wale
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

6.  Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves.

Authors:  E J Ishac; L Jiang; K D Lake; K Varga; M E Abood; G Kunos
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

7.  Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine.

Authors:  R G Pertwee; S R Fernando; J E Nash; A A Coutts
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

Review 9.  Modulation of noradrenaline release through activation of presynaptic beta-adrenoreceptors.

Authors:  H Majewski
Journal:  J Auton Pharmacol       Date:  1983-03

10.  Presynaptic regulation of the release of catecholamines.

Authors:  S Z Langer
Journal:  Pharmacol Rev       Date:  1980-12       Impact factor: 25.468

View more
  18 in total

1.  Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.

Authors:  Adèle Thomas; Lesley A Stevenson; Kerrie N Wease; Martin R Price; Gemma Baillie; Ruth A Ross; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

2.  Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor.

Authors:  Kirsten Schulte; Nina Steingrüber; Bernd Jergas; Agnes Redmer; Christina Maria Kurz; Rainer Buchalla; Beat Lutz; Andreas Zimmer; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-01-04       Impact factor: 3.000

3.  Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system.

Authors:  Torsten Pfitzer; Nathalie Niederhoffer; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-20       Impact factor: 3.000

4.  Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release.

Authors:  Eberhard Schlicker; Agnes Redmer; Andre Werner; Markus Kathmann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

5.  Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.

Authors:  M G Cascio; L A Gauson; L A Stevenson; R A Ross; R G Pertwee
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

6.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

7.  Crosstalk between presynaptic angiotensin receptors, bradykinin receptors and alpha 2-autoreceptors in sympathetic neurons: a study in alpha 2-adrenoceptor-deficient mice.

Authors:  Anne-Ulrike Trendelenburg; Angelika Meyer; Werner Klebroff; Serafim Guimarães; Klaus Starke
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

8.  Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain.

Authors:  David Moranta; Susana Esteban; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-16       Impact factor: 3.000

9.  3H-Noradrenaline release from mouse iris-ciliary body: role of presynaptic muscarinic heteroreceptors.

Authors:  Michel Bernhard; Kenneth Takeda; Caroline Keller; Mirko Haslebacher; George N Lambrou; Anne-Ulrike Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-16       Impact factor: 3.000

10.  Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs.

Authors:  Eiji Hashiba; Kazuyoshi Hirota; Tsuyoshi Kudo; Girolamo Calo'; Remo Guerrini; Akitomo Matsuki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-03-08       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.